Whats new?

Latest News

Keep up with the latest news from research breakthroughs to company news

BAFASAL® Moves Closer to EU Authorisation

Following the Standing Committee on Plants, Animals, Food and Feed (PAFF Committee) recent meeting in Brussels, Proteon Pharmaceuticals is pleased to share a significant development regarding BAFASAL®, our first bacteriophage-based zootechnical feed additive for poultry.

According to the publicly available agenda of the PAFF Committees, the draft Regulation for BAFASAL® was scheduled for a vote by EU Member States on 12–13 May 2025.

We have now been informally notified that the draft received a qualified majority vote and is now entering the next formal steps: translation, adoption by the European Commission, and publication in the Official Journal of the European Union.

Once the final regulatory procedures are completed, the authorisation of BAFASAL® will mark a historic milestone in bacteriophage innovation, becoming the first bacteriophage-based zootechnical feed additive approved for use in poultry across the EU.

“This development represents a defining moment for Proteon and bacteriophage technology,” said Prof. Jarosław Dastych, CEO of Proteon Pharmaceuticals. “It highlights the role of targeted, science-based approaches in addressing major challenges such as food safety and antimicrobial resistance.”

„This breakthrough confirms Proteon’s leadership in innovation and marks the beginning of a broader impact for phage-based solutions in the EU,” commented Łukasz Dziekoński, Member of the Supervisory Board of Proteon Pharmaceuticals.

The forthcoming authorisation follows a detailed scientific evaluation by the European Food Safety Authority (EFSA), which confirmed BAFASAL®’s safety and efficacy in reducing Salmonella Enteritidis contamination when administered via drinking water or liquid complementary for all poultry species (EFSA Journal 2024;22(12):9132).

“This step forward reflects years of dedicated research and regulatory engagement, and demonstrates that phage-based innovations are gaining recognition within the EU framework,” added Dr Małgorzata Stańczyk, Chief Registration & IP Officer of Proteon Pharmaceuticals. 

We will share the formal publication once it is released in the Official Journal of the European Union, expected in the coming weeks.

Product Overview

The right solution one click away!
Proteon Pharmaceuticals proprietary Phage Development Platform contains world class tools and processes.